Share on StockTwits

Enzon Pharmaceuticals (NASDAQ:ENZN) was upgraded by investment analysts at TheStreet from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

The analysts wrote, “Enzon Pharmaceuticals (ENZN) has been upgraded by TheStreet Ratings from sell to hold. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and attractive valuation levels. However, as a counter to these strengths, we find that revenues have generally been declining.”

Shares of Enzon Pharmaceuticals (NASDAQ:ENZN) traded down 7.27% during mid-day trading on Tuesday, hitting $1.02. 323,695 shares of the company’s stock traded hands. Enzon Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $2.09. The stock’s 50-day moving average is $1.00 and its 200-day moving average is $1.01. The company has a market cap of $45.0 million and a P/E ratio of 2.09.

Enzon Pharmaceuticals, Inc (NASDAQ:ENZN) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.